

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/019,205		03/12/2002	Robert Boigegrain	IVD 1137	4043	
27546	7590	09/10/2004	EXAMINER		INER	
SANOFI-SYNTHELABO INC.				COLEMAN, BR	COLEMAN, BRENDA LIBBY	
9 GREAT V P.O. BOX 3		PARKWAY		ART UNIT	PAPER NUMBER	
MALVERN, PA 19355				1624		

DATE MAILED: 09/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	A II AI NI	A 11					
•	Application No.	Applicant(s)					
Office Action Comments	10/019,205	BOIGEGRAIN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Brenda Coleman	1624					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period where the reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	rely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. & 133)					
Status							
1) Responsive to communication(s) filed on	_·						
2a) ☐ This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E.	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) <u>1-35</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-5 and 9-35</u> is/are rejected.	Claim(s) <u>1-5 and 9-35</u> is/are rejected.						
7) Claim(s) <u>6-8</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examiner	·.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the o	Irawing(s) be held in abeyance. See	37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction							
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Application ty documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Dai 5) Notice of Informal Pa	e					
Paper No(s)/Mail Date 12/19/01.	6) Other:	nem Application (PTO-152)					

Application/Control Number: 10/019,205

Art Unit: 1624

DETAILED ACTION

Claims 1-35 are pending in the application.

Election/Restrictions

- 1. Applicant's election of Group I in the reply filed on June 16, 2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
- 2. Claims 1, 2 and 9-35 are rejected as being drawn to an improper Markush group. The recited compounds, while possessing a common utility, differ widely in structure and are not art-recognized equivalents and are thus, independently distinct for the reasons set forth in the restriction requirement.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 12, 13 and 15-28 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In evaluating the enablement question, several factors are to be considered. In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988); Ex parte Forman, 230

Application/Control Number: 10/019,205

Art Unit: 1624

USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, and 7) the quantity of experimentation needed.

The nature of the instant invention has claims, which embrace substituted azepines, i.e. the instant compounds of formula (I) wherein the R_2 and R_3 form a 7-membered ring. Claims 13 and 22-28 are to a method of treating psychotic disorders. The specification, while being enabling for schizophrenia, does not reasonably provide enablement for all psychotic disorders. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The psychotic conditions of claims 13 and 22-28 are not described in the specification. While the specification provides for the use of the azepine compounds of the instant invention in the treatment of schizophrenia, there is no description for the broad genus, psychotic conditions. There must be evidence to justify the contention that the claimed compounds can be useful in the treatment of "psychotic disorders". It is difficult to treat many of the disorders claimed herein.

In general, pharmacological activity is a very unpredictable area. In cases involving physiological activity "the scope of the enablement obviously varies inversely with the degree of unpredictability of the factors involved." In re Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970). Since this case involves unpredictable in-vivo

Application/Control Number: 10/019,205

Art Unit: 1624

physiological activities, the scope of the enablement given in the disclosure presented here was found to be low.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

- 4. Claims 3-5, 9-11, 16-18, 23-25 and 30-32 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:
 - a) Claim 3 and claims dependent thereon are vague and indefinite in that it is not known what is meant by the definition of R_1 which is not stated in a proper Markush form, i.e. there are two definitions for R_1 .
 - b) Claim 9 is vague and indefinite in that it is not known what is meant by (I) in the 2nd and 3rd lines from the bottom of page 4 and the 2nd, 4th, 13th, 17th and 19th line of page 5 in the claim. There is no (I) in the claim.
 - c) Claim 10 and claims dependent thereon are vague and indefinite in that it is not known what is meant by nascent hydrogen.
 - d) Claim 10 is vague and indefinite in that it is not known what is meant by (I) in the 3rd, 4th, 6th, 7th and 8th lines of page 6 in the claim. There is no (I) in the claim.
 - e) Claim 11 is vague and indefinite in that it is not known what is meant by (I) in the 2nd line of the claim. There is no (I) in the claim.

Art Unit: 1624

Claim Objections

5. Claims 6-8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 571-272-0674. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brenda Coleman

Primary Examiner Art Unit 1624

September 5, 2004